Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple sclerosis
Biotech
Acelyrin to be absorbed into Alumis in all-stock merger
Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.
James Waldron
Feb 7, 2025 5:35am
Investigational MS drug restores mobility in mice
Jan 2, 2025 2:15pm
Sanofi will deploy new AI tool in late-stage MS trials
Nov 13, 2024 7:40am
Sanofi flunks MS study, dealing another blow to Denali pact
Oct 11, 2024 5:56am
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
Sep 20, 2024 7:07am
Sanofi's tolebrutinib fails 2 of 3 late-stage MS trials
Sep 2, 2024 1:00am